SI
XBI icon

Stephens Inc’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Stephens Inc’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$361K Sell
2,280
-45
-2% -$6.08K ﹤0.01% 1004
2026
Q1 		$297K Hold
2,325
– – ﹤0.01% 1039
2025
Q4 		$283K Sell
2,325
-75
-3% -$8.6K ﹤0.01% 1066
2025
Q3 		$240K Sell
2,400
-25
-1% -$2.25K ﹤0.01% 1144
2025
Q2 		$201K Sell
2,425
-585
-19% -$46.7K ﹤0.01% 1173
2025
Q1 		$244K Buy
3,010
+30
+1% +$2.68K ﹤0.01% 1070
2024
Q4 		$268K Hold
2,980
– – ﹤0.01% 1062
2024
Q3 		$294K Sell
2,980
-2,940
-50% -$289K ﹤0.01% 1036
2024
Q2 		$549K Sell
5,920
-465
-7% -$41.7K 0.01% 752
2024
Q1 		$606K Sell
6,385
-35
-0.5% -$3.25K 0.01% 735
2023
Q4 		$573K Sell
6,420
-5,692
-47% -$423K 0.01% 698
2023
Q3 		$884K Sell
12,112
-1,465
-11% -$117K 0.02% 549
2023
Q2 		$1.13M Sell
13,577
-8,895
-40% -$744K 0.02% 520
2023
Q1 		$1.71M Buy
22,472
+1,606
+8% +$133K 0.03% 422
2022
Q4 		$1.73M Sell
20,866
-49,687
-70% -$4.02M 0.04% 401
2022
Q3 		$5.6M Buy
70,553
+56,652
+408% +$4.78M 0.12% 189
2022
Q2 		$1.03M Buy
+13,901
New +$1.04M 0.02% 514
2022
Q1 		– Sell
-8,612
Closed -$964K – 1406
2021
Q4 		$964K Sell
8,612
-1,925
-18% -$232K 0.01% 644
2021
Q3 		$1.32M Sell
10,537
-325
-3% -$41.9K 0.02% 565
2021
Q2 		$1.47M Sell
10,862
-45
-0.4% -$5.92K 0.02% 552
2021
Q1 		$1.48M Sell
10,907
-1,495
-12% -$224K 0.02% 520
2020
Q4 		$1.75M Buy
12,402
+33
+0.3% +$4.23K 0.03% 456
2020
Q3 		$1.38M Buy
12,369
+45
+0.4% +$5.04K 0.03% 463
2020
Q2 		$1.38M Buy
12,324
+450
+4% +$44.3K 0.03% 443
2020
Q1 		$920K Buy
11,874
+646
+6% +$57.2K 0.02% 488
2019
Q4 		$1.07M Buy
11,228
+50
+0.4% +$4.33K 0.02% 536
2019
Q3 		$852K Sell
11,178
-1,007
-8% -$83.7K 0.02% 599
2019
Q2 		$1.07M Buy
12,185
+268
+2% +$22.9K 0.02% 560
2019
Q1 		$1.08M Buy
11,917
+1,800
+18% +$153K 0.03% 550
2018
Q4 		$726K Buy
+10,117
New +$815K 0.02% 597

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Stephens Inc's XBI Position: Q2 2026 in Review

Stephens Inc reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.9% in Q2 2026, selling an estimated $6.08K and leaving 2,280 shares worth $361K. The position accounts for ﹤0.01% of the portfolio, ranked #1004.

Stephens Inc first reported a position in XBI in Q4 2018 and has held it in 30 quarters since. The position peaked at $5.6M in Q3 2022. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Stephens Inc held 2,280 shares of State Street SPDR S&P Biotech ETF worth $361K as of Q2 2026.
  • Stephens Inc sold 45 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $6.08K.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Stephens Inc's portfolio in Q2 2026, its #1004 holding.
  • Stephens Inc first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and has held it in 30 quarters since.
  • Stephens Inc's State Street SPDR S&P Biotech ETF position peaked at $5.6M in Q3 2022.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Stephens Inc's 13F filing for Q2 2026, filed 29 Jul 2026.